Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICStandard

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Standard Dose
0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Prescription
Summary

Approval overview NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN is listed in Drugs@FDA under application 065187 (ANDA).

Marketing status: Prescription Active ingredient GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2005-10-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN is listed in Drugs@FDA under application 065187 (ANDA). Marketing status: Prescription Active ingredient GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2005-10-28 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription

Interaction Notes

  • No interaction notes stored yet.
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN (GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE) | Drug Monograph | MedicHelpline